Literature DB >> 3396470

Activity of cefotaxime and amikacin against 14,272 gram-negative bacteria from clinical samples in the period 1980 to 1985.

D Dámaso1, M P Sánchez-Moreno, L Martínez-Martínez, E Mesa, F Portero, P Mendaza, R M Daza.   

Abstract

The sensitivity to cefotaxime and amikacin of 14,272 Gram-negative bacilli (Enterobacteriaceae and non-fermenting Gram-negative bacilli) isolated from clinical samples was studied during the period 1980 to 1985. The minimum inhibitory concentration (MIC) was determined by means of diffusion in agar. Strains were considered resistant to cefotaxime and amikacin if the MIC values were greater than 16 mg/L and greater than 8 mg/L, respectively. The MIC90 reached the critical value for cefotaxime in the case of Citrobacter spp., Escherichia coli, Klebsiella spp., Proteus mirabilis, Salmonella spp. and Shigella spp., and for amikacin in the case of Citrobacter spp., Enterobacter spp., E. coli, Klebsiella spp., P. mirabilis, Proteus vulgaris, Salmonella spp. and Serratia spp. Only Shigella spp. were sensitive to cefotaxime but not to amikacin, and only strains of Enterobacter spp. and Serratia spp. were sensitive to amikacin but not to cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396470     DOI: 10.2165/00003495-198800352-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  3 in total

1.  Surveillance of aminoglycoside resistance. European data.

Authors:  H W Van Landuyt; J Boelaert; B Glibert; B Gordts; A M Verbruggen
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

2.  [Cefotaxime in infections caused by multi-resistant microorganisms].

Authors:  M Aguirre; A Torres; J M Alés
Journal:  Rev Clin Esp       Date:  1981-01-15       Impact factor: 1.556

3.  Five-year surveillance of aminoglycoside usage in a university hospital.

Authors:  R F Betts; W M Valenti; S W Chapman; T Chonmaitree; G Mowrer; P Pincus; M Messner; R Robertson
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.